Evidence map›Paper›PMID 35134389›Full record

ReviewAnalytical biochemistry2022

Measurement of neutral ceramidase activity in vitro and in vivo.

Michael Simoes, Amalia Saleh, Yong-Mi Choi, Michael V Airola, John D Haley, Nicolas Coant

Open access · greenAbstract readReview
In one paragraph

Review in Analytical biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael SimoesDepartment of Pathology and Stony Brook Cancer Center, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794, USA.
Amalia SalehDepartment of Pathology and Stony Brook Cancer Center, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794, USA.
Yong-Mi ChoiDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794, USA.
Michael V AirolaDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, 11794, USA.
John D HaleyDepartment of Pathology and Stony Brook Cancer Center, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794, USA.
Nicolas CoantDepartment of Pathology and Stony Brook Cancer Center, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794, USA. Electronic address: nicolas.coant@stonybrookmedicine.edu.
Stony Brook School · USStony Brook University · US

Funding

Development of neutral ceramidase inhibitor tool compoundsR01CA221948 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HALEY, JOHN DOUGLAS, SCAMPAVIA, LOUIS DANIEL · 2018 to 2020
$1.3M
NCI NIH HHS R01 CA221948
6 · The paper itself

Abstract

Neutral ceramidase is a hydrolase of ceramide that has been implicated in multiple biologic processes, including inflammation and oncogenesis. Ceramides and other sphingolipids, belong to a family of N-acyl linked lipids that are biologically active in signaling, despite their limited structural functions. Ceramides are generally pro-apoptotic, while sphingosine and sphingosine-1-phosphate (S1P) exert proliferative and pro-oncogenic effects. Ceramidases are important regulators of ceramide levels that hydrolyze ceramide to sphingosine. Thus, ceramidase inhibition significantly increases the quantities of ceramide and its associated signaling. To better understand the function of ceramide, biochemical and cellular assays for enzymatic activity were developed and validated to identify inhibitors of human neutral ceramidase (nCDase). Here we review the measurement of nCDase activity both in vitro and in vivo.

Indexed as

HumansNeutral CeramidasePseudomonas aeruginosaNeutral CeramidaseCeramidesNeutral ceramidaseNeutral ceramidase enzymatic assays

Identifiers

PMID35134389
PMCPMC11787886
OpenAlexW4210753765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.